India To Weed Out 156 Irrational FDCs; Legal Challenge Underway bit.ly/4e10n6S #PinkSheet

At a recent policy forum, experts discussed what challenges Korea is facing in its quest to build global-level biopharma clusters, including governance, discontinuity of and insufficient investment, as well as need to attract foreign firms Pink Sheet, Citeline Regulatory pink.citeline.com/PS155192/Clust…

In this week's Scrip, Citeline Commercial #podcast (free access): J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth. #pharma #biotech scrip.citeline.com/SC150865/Quick…

J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso. Survival and other benefits with J&J’s EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca’s Tagrisso in first-line EGFR-mutant...... ow.ly/OGAH105I5Qv #PharmaScrip

.Vibha Ravi talks to former Hilleman CEO Davinder Gill for Scrip, Citeline Commercial #pharma #vaccines scrip.citeline.com/SC150857/Forme…

🌟 News. Context. Impact: your weekly premium content roundup. Click below to read individual articles. Check back next week for more! Scrip—ow.ly/hZtr50TfHAu. Pink Sheet—ow.ly/AMLt50TfHAt. In Vivo—ow.ly/ntQY50TfHAw. Medtech Insight—ow.ly/3IHk50TfHAq.

Join Jung Won Shin in her latest Korean-language mini #podcast, this episode on J&J's plans in #obesity. On your usual platforms incl. Spotify below: open.spotify.com/episode/6ajZ3g…

Glenmark Shells Out Another $25m To Resolve Civil Price-Fixing Charges pink.citeline.com/articles/2024/…

Join Lisa Takagi in her latest Japanese-language mini #podcast, this time looking at Chinese #pharma firms' rising clinical trials in Japan. On your usual platforms incl. @spotify below. open.spotify.com/episode/7KKah4…

It was great talking to Mr. Gill (former CEO, Hilleman and VP, Pfizer). His openness to ideas led to an early stage project exploring the use of human milk biome and others like Bharat Biotech's cholera vaccine #research #biotechinnovation #microbiome #vaccine Davinder Gill, PhD

It's time for our new Citeline Monthly Highlights! Here are some of August's latest news and updates from our brands. Check out the latest news, insights, and updates!

We are proud to join forces with Greenphire - this partnership is a huge step in how we will create next generation products at Citeline. Read how our complementary datasets will support sponsors and CROs in clinical trial planning! ow.ly/8Svg50Tj7vl.

Great speaking with Mr. Gill (former CEO, Hilleman; VP, Pfizer) whose openness to ideas led to an early stage project on use of human milk microbiome and late stage ones like the oral cholera vaccine launched by Bharat Biotech #research #biotechinnovation scrip.citeline.com/SC150857/Forme…

Bharat Biotech to co-develop, commercialize Alopexx Inc's broad-spectrum antimicrobial vaccine #pharmaceutical #research #Marketing #vaccines

GSK Drops Blockbuster Hope Herpes Vaccine After Phase II Disappointment by Andrew McConaghie #vaccines #biotech #Pharmaceutical $GSK scrip.citeline.com/articles/2024/…

Intercept's obeticholic acid faces hurdles in shift from US FDA accelerated to regular approval for patients with PBC without cirrhosis or with compensated cirrhosis, by Sue Sutter #research #regulatory #FDA pink.citeline.com/PS155223/Ocali…

Korea has cut the review and approval period for new drugs to 295 days from 420 days reports Jung Won Shin #regulatory #pharmaceutical #biotech pink.citeline.com/PS155224/Korea…

Japan brings down more barriers to drug approvals. A report by Lisa Takagi #regulatory #pharmaceuticals #biotech

Aurobindo to acquire remaining 49% in existing subsidiary GLS Pharma, oncology products company, from founding family for INR225 million #Pharmaceuticals #Deals #acquisitions